Navigation Links
Poniard Pharmaceuticals Completes Enrollment of Phase 2 Picoplatin Trial in Colorectal Cancer
Date:5/6/2008

- Preliminary Phase 1 and 2 Data Expected at ASCO in June -

SOUTH SAN FRANCISCO, Calif., May 6 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced that it has completed patient enrollment in its Phase 2 clinical trial evaluating picoplatin combination chemotherapy for the first-line treatment of metastatic colorectal cancer (CRC). Early data from this trial are expected in the second half of 2008. Picoplatin, the Company's lead product candidate, is a new generation platinum chemotherapy agent with the potential to become a platform product addressing multiple indications, combinations and formulations.

"Picoplatin, to date, has demonstrated good tolerability, with no severe neuropathies when combined with 5-fluorouracil and leucovorin in the FOLPI regimen. In our Phase 2 trial, we are performing a head-to-head comparison of the efficacy and safety of picoplatin with oxaliplatin. We will be presenting preliminary Phase 2 data and updated Phase 1 data at the 2008 American Society of Clinical Oncology (ASCO) Annual Meeting, and we anticipate more clinical data this year for presentations at various scientific meetings," said Robert De Jager, M.D., chief medical officer of Poniard. "The data from our ongoing Phase 2 trial could establish picoplatin as a platform product and provide a solid foundation for supporting additional registration trials, thereby expanding the potential of this product."

Picoplatin is a chemotherapeutic agent that has an improved safety profile compared to existing platinum-based chemotherapeutics. It was designed to overcome platinum resistance associated with the treatment of solid tumors. Picoplatin has be
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
2. Poniard Pharmaceuticals Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial
3. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
4. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
5. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
6. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
7. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
8. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
9. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
10. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
11. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 28, 2014 Reportlinker.com announces that a ... catalogue: North America Laparoscopes Market Outlook ... North America Laparoscopes Market Outlook to ... America Laparoscopes Market Outlook to 2020", provides key ... The report provides value, in millions of US ...
(Date:8/28/2014)... 2014 /PRNewswire-iReach/ -- CountryFocus: Healthcare, Regulatory and Reimbursement ... (Photo - http://photos.prnewswire.com/prnh/20140828/140879 ) ... Reimbursement Landscape Poland " an essential source of ... healthcare market and provides insights into the demographic, ... the report provides valuable insights into the trends ...
(Date:8/28/2014)... China , Aug. 28, 2014 ... TPI ), a pharmaceutical company that specializes in ... generics and active pharmaceutical ingredients (API) today updates ... Company,s Qionglai Facility (QLF). The ... Practice (GMP) dataset for China Food & Drug ...
Breaking Medicine Technology:North America Laparoscopes Market Outlook to 2020 2North America Laparoscopes Market Outlook to 2020 3North America Laparoscopes Market Outlook to 2020 4North America Laparoscopes Market Outlook to 2020 5North America Laparoscopes Market Outlook to 2020 6North America Laparoscopes Market Outlook to 2020 7North America Laparoscopes Market Outlook to 2020 8North America Laparoscopes Market Outlook to 2020 9North America Laparoscopes Market Outlook to 2020 10North America Laparoscopes Market Outlook to 2020 11Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 2Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 3Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 4Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 5TPI Submits Dataset for GMP Inspection at Qionglai Facility (QLF) 2
... Reportlinker.com announces that a new market research ... Patient Self-Monitoring: Devices, Markets, Players ... http://www.reportlinker.com/p0581171/Patient-Self-Monitoring-Devices-Markets-Players-and-Prospects .html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic The ... serum levels is deemed to be a ...
... A new patent covering tumor suppression technologies, including the ... awarded to The University of Texas System ... to the discovery that chromosome 3p21.3 genes act as ... also known as FUS1, the anti-cancer agent in ...
Cached Medicine Technology:Patient Self-Monitoring: Devices, Markets, Players and Prospects 2Patient Self-Monitoring: Devices, Markets, Players and Prospects 3Genprex Announces New Patent Issuance in Japan 2
(Date:8/28/2014)... Valero Renewable Fuels Company, LLC, a ... and the Ports of Indiana hosted Lt. Gov. Sue ... a Port Appreciation and Welcome Celebration commemorating the restart ... “The opening of Valero’s ethanol facility at the ... win for the State of Indiana,” Ellspermann said. “When ...
(Date:8/28/2014)... 2014 Gurnick Academy of Medical Arts ... is re-accredited for the 5 years of the accreditation ... (ARMRIT). , “We are very proud to have ... program to make sure we provide the best experience ... in MRI field nowadays and I look forward to ...
(Date:8/28/2014)... Norton HealthDay Reporter THURSDAY, ... sending electrical currents through the scalp to a specific network ... a day. In a small study of healthy young ... certain networks involved in memory. That, in turn, boosted participants, ... after the brain stimulation. During TMS, an electromagnetic coil ...
(Date:8/28/2014)... fermentation," when yeast that should be busily converting grape ... leaving the remaining sugar to instead be consumed by ... of researchers including UC Davis yeast geneticist Linda Bisson ... Working through a prion -- an abnormally shaped ... bacteria in fermenting wine to switch yeast from sugar ...
(Date:8/28/2014)... Chicago, IL (PRWEB) August 28, 2014 ... IT Supplement shows that while most hospitals utilize a ... of health care information technology is still a challenge. ... in the August issue of Health Affairs , ... Health Forum’s Health Care Data Center, as well as ...
Breaking Medicine News(10 mins):Health News:Valero, Ports of Indiana Celebrate Restart of Ethanol Plant 2Health News:Valero, Ports of Indiana Celebrate Restart of Ethanol Plant 3Health News:Gurnick Academy’s MRI Program Is Re-Accredited by ARMRIT for the 5 Years 2Health News:Electrical Pulses to Scalp May Boost Memory: Study 2Health News:Electrical Pulses to Scalp May Boost Memory: Study 3Health News:Prions can trigger 'stuck' wine fermentations, researchers find 2Health News:AHA Data Shows Progress, Challenges on Road to Healthcare IT Adoption 2Health News:AHA Data Shows Progress, Challenges on Road to Healthcare IT Adoption 3
... her down but along with her, her families too have to ... brain //and breast has taken its toll on Ellen who is ... the illness. Her family could seem to do nothing to ease ... quarters- the palliative care team at Dartmouth Hitchcock Medical Center. ...
... get married is a waste of breath, a US expert ... // ,William Smith, the vice president of the Sexuality, ... a six-year study commissioned by the US Congress found that ... on pushing sexual abstinence outside marriage had had no discernible ...
... day of reckoning is only getting closer for the Bush ... //The most recent, is the one cited by the American ... the information provided by the federally sponsored ‘Abstinence Only Sex ... way of a lengthy document compiled by Dr. John Santelli, ...
... ‘chemo brain’ that chemotherapy patients complain about, is finally ... especially women have for years informed their doctors about ... to concentrate, difficulty retrieving words, trouble with multitasking and ... edge. Once brushing such complaints aside, these very people, ...
... breakthrough method of blood test to diagnose Parkinson disease. This ... before the symptoms arrive. The test is done by a ... Melbourne University specialists. ,They have also created a ... it can screen many types of PD and monitor treatment ...
... is no evidence that antioxidant supplements interfere with ... a recent systematic //review of the use of ... increase survival rates, tumor response, and the patient’s ... implications for patients whose oncologists discourage the use ...
Cached Medicine News:Health News:The Pain Relieved With the Help of Palliative Workers 2Health News:Chemo Brain- Nothing Forgettable About It 2Health News:Chemo Brain- Nothing Forgettable About It 3Health News:New Blood Test to Diagnose Parkinson Disease 2Health News:Antioxidants May Aid Chemotherapy Patients 2